Clinical Trial Update: A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating daratumumab in transplant-eligible patients with previously untreated multiple myeloma has completed. Results were posted on 2025-04-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Intergroupe Francophone du Myelome | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2025-04-13